|
|
|
|
|
| January 5, 2012 | ISSUE NUMBER 232 VOL 8 |
|
2012 Forecast
Hard Times Before the Harvest
Big Pharma digs in for a year of transition as the seeds of a pipeline revival take root, writes William Looney ...Read More
Regulatory
Off-Label Comments Online: Keep Doing What You're Doing, Says FDA
Those in favor of a less-is-more approach to FDA social media guidelines got what they wanted for the holidays: a trim, 15-page document on how to respond to unsolicited off-label comments ...Read More
Global
Arise Sir Andrew (Witty)
Pharma gets a boost in the UK’s New Year’s Honors List with the knighthood of the GSK leader ...Read More
Company Spotlight
Ranbaxy's New Year's Resolution
Right now, many of us are thinking of how we could improve ourselves during the New Year. Others, such as Ranbaxy, will be forced to improve themselves in 2012, writes Erik Greb ...Read more
Ad Stars 2012
Call For Entries
It’s that time again for the editors of Pharm Exec to narrow down its choices for our annual Ad Stars feature, recognizing the most clever, unique, and effective campaigns in pharma advertising over the past year. We’d like to extend an opportunity for you to submit an ad for consideration. Please feel free to share with us the campaign that your firm or agency feels truly helps the client stand apart from its competition ...For more information |
|
|
 // Oxygen Biotherapeutics (Morrisville, N.C.) named Chris A. Rallis, Executive-in-Residence at Pappas Ventures, and Anthony A. DiTonno, President and Chief Executive Officer of NeurogesX (San Mateo, Calif.) to serve as members of the company's Board of Directors.
// NeurogesX also announced Ronald A. Martell's appointment as President, Chief Executive Officer, and board member. // Kantar Health (New York) appointed Debbie Warner as Vice President in the Commercial Planning group. // Cetero Research (Cary, N.C.) announced two new appointments to its senior management team. Michael C. Fillios was named Chief Administrative Officer; and David Coggin was named Vice President, Biometrics. // Dicerna Pharmaceuticals (Watertown, Mass.) announced the appointment of James B. Weissman to Chief Business Officer.
|
|
|
|
|
|
|
 |
| |
 |
 |
|
 |
Which of the following was the most significant in influencing a change in your business strategy in 2011?
Competitive Threats
The Economy
Regulation
Shareholder Expectations
|
|
|
|
|
You
are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To
ensure delivery to your Inbox, please add us to your
address book. If you need help doing this, click
here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
